Relationship between N-Terminal Pro B-Type Natriuretic Peptide and Body Mass Index

Year 2013, , 32 - 35, 01.01.2013

Şafak Şahin Faruk Kutlutürk Türker Taşlıyurt Banu Öztürk Berna Yelken

https://doi.org/10.5505/abantmedj.2013.27247

Abstract

Objective: N-terminal pro B-type natriuretic peptide NT-pro BNP is secreted from the cardiac ventricles in response to volume expansion. The effect of obesity on natriuretic peptide has yet to be fully elucidated. We aimed to compare the NT-pro BNP levels in obese and in healthy individuals with normal body mass index. Method: Forty-two obese patients 37 women, 5 men; body mass index ≥ 30 and thirty-five normal body mass index individuals 27 women, 8 men; body mass index ≤ 25 were analyzed regarding NT-pro BNP. Results: The serum levels of NT-pro BNP was significantly higher in obese patients than normal body mass index individuals p=0,027 . No correlation was found between body mass index and NT-pro BNP. Statistically significant difference was found between systolic and diastolic blood pressures in both groups p

Keywords

obesity, N-terminal proB-type natriuretic peptide, hypertension

N-Terminal Pro B-Tip Natriüretik Peptit ve Vücut Kitle İndeksi arasındaki ilişki

Abstract

Amaç: N-terminal pro B-tip natriüretik peptid NT-pro BNP hacim genişlemesinde yanıt olarak kardiyak ventriküllerden salgılanır. Natriüretik peptid üzerine obezitenin etkisi henüz tam olarak aydınlatılmış değildir. Bu çalışmada normal kilolu ve obez bireylerde NT-pro BNP düzeylerinin karşılaştırılması amaçlandı. Yöntem: Çalışmaya kırkiki obez hasta 37 kadın, 5 erkek; vücut kitle indeksi ≥ 30 ve normal kilolu otuzbeş kişi 27 kadın, 8 erkek; vücut kitle indeksi ≤ 25 kontrol grubu olarak alındı. Hasta ve kontrol grubunun NT-pro BNP düzeyleri karşılaştırıldı. Bulgular: NT-pro BNP düzeyleri obez hastalarda kontrol grubuna göre anlamlı olarak yüksek bulundu p=0.027 . Vücut kitle indeksi ile NT-pro BNP arasında korelasyon yoktu. Obez hastalarda sistolik ve diyastolik kan basınçları istatistiksel olarak yüksekti sırasıyla; p

Keywords

obezite, N-terminal pro B-tip natriüretik peptid, hipertansiyon

References

• Kenchaiah S, Evans JC, Levy Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vassan RS, Obesity and the risk of heart failure. N Engl J Med. 2002; 347:305-13
• Lauer MS, Anderson KM, Kannel WB, Levy D. The impact of obesity on left ventricular mass and geome- try JAMA 1991; 266:231-6
• Reisin E, Messerli FH. Obesity-related hypertension: mechanisms, cardiovascular risks, and heredity. Curr Opin Nephrol Hyperten 1995; 4:67-71
• Rocchini AP, Moorehead CP, DeRemer S, Bondie D. Pathogenesis of weight related changes in blood pressure in dogs. Hypertension 1989; 13:922-8
• Rocchini AP. Insulin resistance and blood pressure regulation in obese and non-obese subjects. Hyper- tension 1991; 17: 837-42
• Rocchini AP, Key S, Bondie D. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescent. N Engl J Med 1989; 321: 580-5
• Levin ER, Gardner DG, Samson WK. Natriuretic pep- tids. N Engl J Med 1998; 339: 312-28
• Schirmer H, Omland T. Circulating N-terminal pro- atrial natriuretic peptide is an independent predictor of left ventricular hypertrophy in the general popula- tion. The Tromso Study. Eur Heart J. 1999; 20: 755-63
• Lerman A, Gibbons RJ, Rodeheffer RJ, McKinley LJ, Heublein DM, Burnett JC Jr. Circulating N-terminal atrial natriuretic peptide as a marker for symptom less left-ventricular dysfunction. Lancet 1993; 341: 1105-9
• McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, Tunstall-Pedoe H, McMurray JJ, Dargie HJ. Biochemical detection of left ventricular systolic dysfunction. Lancet 1998; 351: 9-13.
• Cowie MR, Struthers AD, Wood DA, Coats AJ, Thomp- son SG, Poole-Wilson PA, Sutton GC. Value of natriu- retic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349-53
• Messerli FH, Ventura HO, Reisin E, Dreslinski GR, Dunn FG, MacPhee AA, Frohlich ED. Borderline hyper- tension and obesity: two prehypertensivestate with elevated cardiac output. Circulation. 1982; 66: 55-60
• Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PW, Sutherland P, Omland T, Vasan RS. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002; 90:254-8
• Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, Vasan RS. Impact of obesity o plasma na- triuretic peptide levels. Circulation 2004; 109:594-600
• Licata G, Volpe M, Scaglione R, Rubattu S. Salt- regulating hormones in young normotensive obese subjects of saline load. Hypertension. 1994; 23: 120-4
• Sarzani R, Dessi-Fulgheri P, Paci VM, Espinosa E, Rap- pelli A. Expression of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol Invest. 1996; 19: 581-5
• Sarzani R, Dessi-Fulgheri P, Salvi F, Serenelli M, Spagnolo D, Cola G, Pupita M, Giantomassi L, Rappelli A. A novel promoter variant of the natriuretic peptide clearance receptor gene is associated with lower atri- al natriuretic peptide and higher blood pressure in obese hypertensives. J Hypertens. 1999; 17: 1301-5.
• Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson DJ, Oparil S, Wright JT, Roccella EJ, and the National High Blood Pressure Education Program Coordinating Commit- tee. The Seventh Report of the Joint National Com- mittee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289: 260-72
• Yamamoto, K, Burnett, JC, Jougaski, M, Nishimura RA, Bailey KR, Saito Y, Nakao K, Redfield MM. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ven- tricular hypertrophy Hypertension. 1996; 28: 988-94
• Luchner A, Burnett JC, Jr. Jougasaki M, Hense HW, Heid IM, Muders F, Riegger GA, Schunkert H. Evalua- tion of brain natriuretic peptide as marker of left ven- tricular dysfunction and hypertrophy in the popula- tion J Hypertens. 2000; 18:1121-8
• Qi W, Mathisen P, Kjekhus J, Simonsen S, Bjİrnerheim R, Endresen K, Hall C. Natriuretic peptides in patients with aortic stenosis Am Heart. 2001; 142:725-32
• Packer M, Cohn JN. Consensus recommendations for the management of chronic heart failure Am J Cardi- ol. 1999; 83: 1-32
• Minami J, Nishikimi T, Ishimitsu T, Makino Y, Kawano Y, Takishita S, Kangawa K, Matsuoka H. Effect of a hy- pocaloric diet on adrenomedullin and natriuretic pep- tides in obese patients with essential hypertension J CardiovascPharmacol. 2000; 36: 83-6
• Messaoudi L, Donckier J, Stoffel M, Ketelslegers JM, Kolanowski J. Changes in blood pressure and in vaso- active and volume regulatory hormones during semis- tarvation in obese subjects. Metabolism. 1998; 47: 592-7.
• Hollister AS, Inagami T. Atrial natriuretic factor and hypertention: a review and metanalysis. Am J Hyper- tens. 1991; 4:850-65.
• Dessi-Fulgheri P, Palermo R, Di Noto G, Conti V, Bald- inelli A, Pupita G, Agostinelli M, Rappelli A. High levels of plasma atrial natriuretic factor and impaired left ventricular diastolic function in hypertensives witout left ventricular hypertrophy. J Hypertens. 1992; 10: 161-5
• Ganau A, Devereux RB, Atlas SA, Pecker M, Roman MJ, Vargiu P, Cody RJ, Laragh JH. Plasma atrial natriu- retic factor in essential hypertension: relation to car- diac size, function and systemic hemodynamics. J Am CollCardiol. 1989; 14: 715-24
• Hanusch-Enserer U, Hermann KM, Cauza E, Spak M, Mähr B, Dunky A, Rosen HR, Köller U, Prager R. Effect of Gastric Banding on Aminoterminal Pro-brain Natri- uretic Peptide in the Morbidly Obese. Obesity Re- search 2003; 11: 695–8